GSE111535 Interleukin-1 β promotes an atheroprotective distribution of smooth muscle cells and macrophages in late stage murine atherosclerotic lesion

Contributors : Delphine Gomez ; Richard A Baylis ; Alexandra A Newman ; Brittany G Durgin ; Gabriel F Alencar ; Sheila E Francis ; Emmanuel Pinteaux ; Gwendalyn J Randolph ; Matthias Nahrendorf ; Philip K Swirski ; Herman Gram ; Paul M Ridker ; Peter Libby ; Gary K OwensSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusDespite decades of research, our understanding of processes controlling the stability of late-stage atherosclerotic plaques remains poor. However, a prevailing hypothesis is that reducing inflammation may improve plaque stability. Indeed, the potent inflammatory cytokine, interleukin-1 β (IL-1β), has been shown to be a key driver of atherosclerosis development. Importantly, the CANTOS Trial recently demonstrated that administration of an anti-IL-1β antibody to high-risk post-myocardial infarction (MI) patients reduced the incidence of recurrent nonfatal MI, but did not reduce t he incidence of cardiovascular death or stroke. As such, although the CANTOS trial results providing exciting evidence that targeting inflammation can have clinical benefit for treating advanced atherosclerosis, extensive further investigation is needed to better understand the mechanisms by which I L-1β inhibition impacts established lesions. Therefore, we performed intervention studies on smooth muscle cell (SMC) lineage tracing mice with advanced atherosclerosis using anti-IL- 1 or IgG control antibodies. Surprisingly, we found no effec...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research